Which agents are described as new GLP-1 receptor agonists for type 2 diabetes or weight loss?

Which agents are described as new GLP-1 receptor agonists for type 2 diabetes or weight loss?

• A. Semaglutide (Ozempic / Wegovy)
• B. Tirzepatide (Mounjaro / Zepbound)
• C. Both Semaglutide and Tirzepatide
• D. None of the above

Answer: (C)

GLP-1 receptor agonists mimic the incretin GLP-1, boosting insulin release when glucose is high, slowing stomach emptying, and reducing appetite, which helps both blood sugar control and weight loss. Semaglutide is a classic GLP-1 receptor agonist used for type 2 diabetes (injections) and for weight management at higher doses. Tirzepatide, while described as a dual GIP and GLP-1 receptor agonist, also activates the GLP-1 receptor, producing the same glucose-lowering and appetite-suppressing effects—with added potential benefits from GIP signaling. Because it engages the GLP-1 receptor and achieves similar or greater effects on glycemic control and weight, it’s regarded as a newer GLP-1 receptor agonist for type 2 diabetes or weight loss.

GLP-1 receptor agonists mimic the incretin GLP-1, boosting insulin release when glucose is high, slowing stomach emptying, and reducing appetite, which helps both blood sugar control and weight loss.

Semaglutide is a classic GLP-1 receptor agonist used for type 2 diabetes (injections) and for weight management at higher doses. Tirzepatide, while described as a dual GIP and GLP-1 receptor agonist, also activates the GLP-1 receptor, producing the same glucose-lowering and appetite-suppressing effects—with added potential benefits from GIP signaling. Because it engages the GLP-1 receptor and achieves similar or greater effects on glycemic control and weight, it’s regarded as a newer GLP-1 receptor agonist for type 2 diabetes or weight loss.